


IN THE CLAIMS

What is claimed is:

1. (ORIGINAL) A compound of the following Formula 1:



wherein

R_A is a C_2 to C_{30} saturated or unsaturated hydrocarbon chain;

R_{10} , R_{11} , R_{13} , R_{14} and R_3 each independently represent H, OH, a C_{1-6} ether, or a saturated or unsaturated hydrocarbon chain which may be substituted with one or more of nitro, halogen, amino, hydroxyl, ketone or aldehyde group;


optionally there is a double bond between C_2 and C_3 of the C ring;

n represents 0 or 1; and

R_B is a C_2 to C_{15} saturated or unsaturated hydrocarbon chain, and where R_B is present, R_A and R_B are both C_2 to C_{12} aliphatic alkyl chains.

2. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in Claim 1~~ wherein at least one of R_{10} , R_{11} and R_{13} represents OH.
3. (CURRENTLY AMENDED) The compound of claim 2, ~~as claimed in Claim 2~~ wherein R_{10} and/or R_{11} represents OH.

4. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 3~~ wherein R_3 , R_{11} and R_{13} all represent OH.
5. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 3~~ wherein R_3 , R_{10} and R_{13} all represent OH.
6. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 5~~ wherein there is a double bond between C_2 and C_3 of the C ring.
7. (CURRENTLY AMENDED) The compound of claim 1, ~~wherein as claimed in any one of Claims 1 to 6~~ where the backbone of R_A has eight, nine or ten carbon atoms.
8. (CURRENTLY AMENDED) The compound of claim 1, ~~wherein as claimed in any one of Claims 1 to 7~~ where R_A is attached to position 7 of the A ring of the flavonoid group.
9. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 8~~ wherein R_A has the following structure:




wherein


n is an integer from 1 to 7; and

m is an integer from 1 to 7.

10. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 8~~ wherein R_A has the following structure:




11. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 8~~ wherein R_A has the following structure:



wherein n is an integer from 2 to 27.

12. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of~~



~~Claims 1 to 8~~ wherein R_A has the following structure:


wherein

x is an integer from 1 to 25;

y is an integer from 1 to 25;

and wherein x + y = 25 or less.

13. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of~~







~~Claims 1 to 12~~ wherein R_A has the following structure:

wherein


n is an integer from 1 to 7; and

m is an integer from 1 to 7.

14. (CURRENTLY AMENDED) The compound of claim 1, ~~as claimed in any one of Claims 1 to 13~~ wherein the flavonoid group has one of the following structures:



15. (CURRENTLY AMENDED) The compound of claim 1 ~~as claimed in any one of Claims 1 to 14~~ having one of the following structures:



INTERNATIONAL APPL. NO.
CLAIMED










INT. FILING DATE

PRIORITY DATE

PCT/GB2003/003054

14 July 2003

13 July 2002



INTERNATIONAL APPL. NO.
CLAIMED


PCT/GB2003/003054

INT. FILING DATE

14 July 2003

PRIORITY DATE

13 July 2002



16. (CURRENTLY AMENDED) A composition comprising a compound of claim 1 ~~as claimed in any one of Claims 1 to 15~~ and at least one pharmaceutical excipient or carrier.
17. (CURRENTLY AMENDED) The composition of claim 16 ~~as claimed in Claim 16~~ which is a sunscreen.
18. (ORIGINAL) A method of preventing UV damage to the skin of a mammalian animal, said method comprising administering a therapeutically effective amount of the composition of Claim 17 to said skin prior to UV exposure.

INTERNATIONAL APPL. NO.
CLAIMED

INT. FILING DATE

PRIORITY DATE

PCT/GB2003/003054


14 July 2003

13 July 2002

19. (ORIGINAL) The method as claimed in Claim 18 wherein said mammalian animal is a human.
20. (CURRENTLY AMENDED) The method of claim 18, ~~as claimed in either one of Claims 18 and 19~~ wherein said composition is applied topically to said skin.
21. (CURRENTLY AMENDED) The composition of claim 16 ~~as claimed in Claim 16~~ which is a skincare composition.
22. (CURRENTLY AMENDED) The composition of claim 21, wherein said composition ~~as claimed in Claim 21~~ further comprises containing emollients and moisturisers.
23. (CANCEL)
24. (CURRENTLY AMENDED) A foodstuff stabiliser composition comprising a compound of claim 1 ~~as claimed in any one of Claims 1 to 15~~.
25. (CURRENTLY AMENDED) The composition of claim 24, wherein said composition ~~is as claimed in Claim 24~~ in the form of an emulsion having a low fat:high water content.
26. (CURRENTLY AMENDED) A method of treating a patient having a disease or disorder involving oxidative damage, said method comprising selecting a patient in need thereof, and ~~the step of~~ administering a therapeutically effective amount of the composition of Claim 16 to said patient.
27. (CURRENTLY AMENDED) The method of claim 26, ~~as claimed in Claim 26~~ wherein said patient is a human.

28. (CURRENTLY AMENDED) The method of claim 26, ~~as claimed in either one of Claims 26 and 27~~ wherein the disease or disorder involving oxidative damage is selected from the group consisting of cancer, heart disease, neurological disorders, auto-immune disorders, ischaemia-reperfusion injury, diabetic complications, septic shock, hepatitis, atherosclerosis and complications arising from HIV or Hepatitis B.
29. (CURRENTLY AMENDED) The method of claim 28, ~~as claimed in Claim 28~~ wherein the disease or disorder is an ischaemia-reperfusion injury or Alzheimer's disease.
30. (CURRENTLY AMENDED) A prophylactic method of treatment to prevent or reduce the severity of a disease or disorder involving oxidative damage in the tissues of a patient, said method comprising selecting a patent in need thereof, and the step of administering a therapeutically effective amount of the composition of Claim 16 to said patient.
31. (CURRENTLY AMENDED) The method of claim 30, ~~as claimed in Claim 30~~ wherein said patient is a human.
32. (CURRENTLY AMENDED) The method of claim 30, ~~as claimed in either one of Claims 30 and 31~~ wherein the disease or disorder involving oxidative damage is selected from the group consisting of cancer, heart disease, neurological disorders, auto-immune disorders, ischaemia-reperfusion injury, diabetic complications, septic shock, hepatitis, atherosclerosis and complications arising from HIV or Hepatitis B.

33. (CURRENTLY AMENDED) The method of claim 32, ~~as claimed in Claim 32~~ wherein the disease or disorder is an ischaemia-reperfusion injury or Alzheimer's disease.
34. (CANCEL)
35. (CANCEL)
36. (CURRENTLY AMENDED) A method of manufacturing a compound of Formula 1 as claimed in claim 1 ~~in any one of Claims 1 to 15~~, said method comprising providing an intermediate compound A and an intermediate compound B, wherein intermediate compound A has the structure $R_A M$ wherein M is a metal or metalloid group where the metal is directly attached to R_A , and R_A is a C_2 to C_{30} saturated or unsaturated alkyl chain, and $R_A M$ is capable of participating in transition metal catalysed cross-coupling reactions; and intermediate compound B has the following structure: wherein



R_{12} represents OH or an O-protecting group


R_3 , R_{10} , R_{11} , R_{13} , and R_{14} each independently represent H, OH, C_1 to C_4 aliphatic alkyl group or an O-protecting group where required, and optionally there is a double bond between C_2 and C_3 of the C ring;

X is a halogen, O-trifluoromethane sulphonate or any other group used in cross-coupling reactions; and


$m = 1$ or 2 ,

and reacting intermediate compound A with intermediate compound B by transition metal catalysed cross-coupling reactions and subsequently deprotecting at least one OH group.


37. (CURRENTLY AMENDED) ~~The A method of claim 36, as claimed in Claim 36~~ wherein $R_A M$ is selected from the group consisting of an organomagnesium, organozinc, organoboron and an ~~or~~ organotin compound.
38. (CURRENTLY AMENDED) The method of claim 36, as claimed in either one of Claims 36 and 37 wherein the catalyst is a palladium, nickel or iron complex.
39. (CURRENTLY AMENDED) A method of manufacturing a compound of Formula 1 as claimed in claim 1, any one of Claims 1 to 15, said method comprising providing an intermediate Compound C and an intermediate Compound D, wherein said intermediate Compound C has the structure $R_A CHCHR$ wherein R_A is as defined in Formula 1, and wherein intermediate Compound D has a structure:



40. (CURRENTLY AMENDED) The method of claim 39, as claimed in Claim 39 wherein the catalyst is:



41. (CURRENTLY AMENDED) A method of manufacturing a compound of Formula 1 as claimed claim 1, ~~in any one of Claims 1 to 15~~, said method comprising providing an intermediate Compound E of formula:



and constructing a flavonol core on said intermediate Compound E.

42. (CURRENTLY AMENDED) The method of claim 41, ~~as claimed in Claim 41~~ wherein said flavonol core is formed by Algar-Flynn-Oyamada (AFO) oxidation.
43. (CURRENTLY AMENDED) The method of claim 41, ~~as claimed in Claim 41~~ wherein said flavanol core is formed by Baker-Verkataraman rearrangement.
44. (CURRENTLY AMENDED) The method of claim 41, ~~as claimed in any one of Claims 40 to 43~~ wherein said intermediate Compound E is formed by a transition metal catalysed cross-coupling reaction.

INTERNATIONAL APPL. NO.
CLAIMED

INT. FILING DATE

PRIORITY DATE

PCT/GB2003/003054

14 July 2003

13 July 2002

45. (CURRENTLY AMENDED) The method of claim 41, ~~as claimed in any one of Claims 40 to 43~~ wherein said intermediate Compound E is formed by alkene cross-metathesis.